版本:
中国

BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016

March 28 Galectin Therapeutics Inc

* Galectin Therapeutics Inc - as of December 31, 2016, company had $15.4 million of non-restricted cash and cash equivalents - sec filing

* Galectin Therapeutics - believes it has sufficient cash to fund currently planned operations and research and development activities through Dec 31

* Galectin Therapeutics Inc - top-line data readout of nash-cx trial remains on track for early December 2017

* Galectin Therapeutics Inc - positive results in studies of gr-md-02 for patients with serious skin diseases Source text - bit.ly/2nHHEas Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐